Among 154 included patients, 80 (51.9%) patients underwent a biopsy of their local/distant relapse which confirmed the HER2-negative tumor status; 87 (57.2%) patients received 3 or more lines of chemotherapy for their metastatic disease. This evidence concerns the gene ERBB2 and neoplasm.